Dose-Response Relationships

The dose-response relationship describes how the magnitude of a drug's effect changes with the dose given or the concentration achieved. Plotted on a logarithmic dose axis it typically forms a sigmoid curve, from which the two defining properties of a drug - its potency (the dose producing a given effect) and its efficacy (the maximum effect attainable) - can be read directly.

Definition

A dose-response relationship is the quantitative relationship between the dose of a drug (or its concentration at the site of action) and the magnitude of the resulting biological effect, typically summarised by a sigmoid log dose-response curve characterised by potency and efficacy.

Scope

This topic covers the quantification of drug action through dose-response and concentration-response curves: the distinction between graded and quantal responses, potency (EC50) versus efficacy (Emax), the slope and the role of the Hill coefficient, and how agonists, partial agonists, and antagonists shift these curves. It is a mechanistic reference entry and does not provide dosing recommendations.

Core questions

• How does drug effect scale with dose or concentration?
• What is the difference between potency (EC50) and efficacy (Emax)?
• How do graded and quantal dose-response curves differ?
• How do competitive and non-competitive antagonists alter the curve?
• What does the Hill coefficient tell us about the steepness of the response?

Key concepts

• Graded versus quantal dose-response
• Potency and EC50
• Efficacy and Emax
• Log dose-response (sigmoid) curve
• Hill coefficient and slope
• Competitive (parallel shift) versus non-competitive antagonism
• Therapeutic index (ED50 vs TD50)

Key theories

Sigmoid (Hill/Emax) concentration-response model

Response rises with the logarithm of concentration along a sigmoid curve defined by Emax and EC50 (and a Hill slope), giving a standard way to express potency and efficacy and to compare drugs quantitatively.

Operational model of agonism

Black and Leff's framework links the observed concentration-response curve to a drug's underlying affinity and efficacy, explaining how partial agonism, spare receptors, and system gain shape the curve's position and maximum.

Mechanisms

As dose or concentration rises, an increasing fraction of target is engaged and the effect grows until it plateaus, producing a sigmoid curve when effect is plotted against the logarithm of concentration. The concentration giving half the maximal effect (EC50) indexes potency, and the plateau (Emax) indexes efficacy; the Hill coefficient describes how steeply effect changes near the EC50. Graded curves describe a continuous effect in a single system, whereas quantal curves describe the proportion of a population reaching a defined all-or-none endpoint and yield population measures such as the ED50. Antagonists reshape the curve diagnostically: a competitive antagonist shifts the agonist curve to the right in parallel without lowering Emax, while a non-competitive antagonist depresses Emax. The operational model of Black and Leff connects these observable features to the drug's intrinsic affinity and efficacy.

Clinical relevance

Dose-response analysis is how potency and efficacy are defined and compared, and the separation between effective and toxic dose ranges underlies the concept of the therapeutic index. The content here describes how drug action is quantified in general and is not a basis for individualised dosing or treatment decisions.

Evidence & guidelines

Potency and efficacy terminology (EC50, Emax, agonist and antagonist effects on the curve) follows IUPHAR quantitative-pharmacology conventions; combination dose-response analysis follows established median-effect and isobologram methods.

History

A. V. Hill's early-twentieth-century equation for ligand binding gave the sigmoid concentration-response its mathematical form, and A. J. Clark applied dose-response analysis systematically to drug action in the 1920s-1930s. The operational model of Black and Leff (1983) and successive IUPHAR nomenclature reports standardised how potency and efficacy are defined and reported, making the dose-response curve the common language of quantitative pharmacology.

Debates

Is potency or efficacy the more important property of a drug?

Potency (EC50) reflects the concentration needed for effect and is often improvable by chemistry, whereas efficacy (Emax) sets the ceiling of achievable response; which matters more depends on the therapeutic goal, and conflating the two is a common interpretive error.

Key figures

• Archibald Vivian Clark
• James Black
• Paul Leff
• Archibald Hill

Seminal works

• black-leff-1983
• neubig-2003
• chou-2006

Frequently asked questions

What is the difference between potency and efficacy?

Potency is the concentration or dose needed to produce a given effect (lower EC50 means more potent), while efficacy is the maximum effect a drug can produce (Emax). A drug can be highly potent yet have low efficacy, as with a partial agonist.

Why is the dose axis usually logarithmic?

Drug effects span a wide range of concentrations, and plotting against the logarithm of dose turns the relationship into a near-symmetric sigmoid, making the EC50 and the slope easy to read and compare across drugs.